中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
36期
13-14
,共2页
肺癌%新辅助化疗%非小细胞肺癌(NSCLC)
肺癌%新輔助化療%非小細胞肺癌(NSCLC)
폐암%신보조화료%비소세포폐암(NSCLC)
Lung cancer%Neoadjuvant chemotherapy%Non small cell lung cancer(NSCLC)
肺癌是威胁人类最为常见的恶性肿瘤之一，其发病率和死亡率均呈日益上升态势。单纯手术治疗或保守治疗的效果均不理想，5年生存率13%左右。肺癌的预防、控制及治疗已成为全世界所关注的焦点之一。近年来，术前诱导化疗，即新辅助化疗被人们所关注，认为其可缩小肿瘤，降低肺癌患者的临床(TNM)分期和消除远处的微转移灶，提高晚期肺癌患者的手术机会和延长患者生存期。新辅助化疗在临床上广为推广，本文将对新辅助化疗在肺癌治疗中的意义进行综述。
肺癌是威脅人類最為常見的噁性腫瘤之一，其髮病率和死亡率均呈日益上升態勢。單純手術治療或保守治療的效果均不理想，5年生存率13%左右。肺癌的預防、控製及治療已成為全世界所關註的焦點之一。近年來，術前誘導化療，即新輔助化療被人們所關註，認為其可縮小腫瘤，降低肺癌患者的臨床(TNM)分期和消除遠處的微轉移竈，提高晚期肺癌患者的手術機會和延長患者生存期。新輔助化療在臨床上廣為推廣，本文將對新輔助化療在肺癌治療中的意義進行綜述。
폐암시위협인류최위상견적악성종류지일，기발병솔화사망솔균정일익상승태세。단순수술치료혹보수치료적효과균불이상，5년생존솔13%좌우。폐암적예방、공제급치료이성위전세계소관주적초점지일。근년래，술전유도화료，즉신보조화료피인문소관주，인위기가축소종류，강저폐암환자적림상(TNM)분기화소제원처적미전이조，제고만기폐암환자적수술궤회화연장환자생존기。신보조화료재림상상엄위추엄，본문장대신보조화료재폐암치료중적의의진행종술。
Lung cancer is one kind of the most common malignant tumor threaten for human,and its morbidity and mortality showed a rising trend.The treatment effect of simple operation or nonoperation was not ideal,and the 5 year survival rate is only about 13% .Lung cancer prevention,control and treatment has become one of the focus of world attention.In recent years, preoperative induction chemotherapy which also been called neoadjuvant chemotherapy has attracted attention by people.It is considered that it can reduce the tumor,reduce the clinical staging of lung cancer patients(TNM) and the elimination of distant micrometastases,and also can improve the operation chance in patients with advanced lung cancer and prolong the survival of patients.Neoadjuvant chemotherapy has been widely promoted in clinic.In this paper,we will review the significance of neoadjuvant chemotherapy in lung cancer.
